IL17A and discoid lupus erythematosus: Of note, two of five lesional DLE datasets demonstrated significant up-regulation of the IL-17 complex and TH17 signature, suggesting that a subset of DLE patients might be responsive to IL-17 neutralization using therapies such as secukinumab, ixekizumab, or brodalumab.